Last updated: February 19, 2026
What is NDC 72733-5901?
NDC 72733-5901 is a biologic drug marketed by Amgen. It is a biosimilar version of a reference biologic, intended for indications including rheumatoid arthritis, plaque psoriasis, and other autoimmune conditions. Approved by the FDA in recent years, the drug targets a broad patient base and benefits from increasing biosimilar adoption.
Market Context and Competitive Landscape
Key Indications and Market Size
| Indication |
Market Size (USD, 2022) |
Notes |
| Rheumatoid arthritis |
15.2 billion |
Largest segment; high drug utilization |
| Psoriasis |
4.5 billion |
Rapidly growing; biosimilar penetration increasing |
| Other autoimmune diseases |
2.3 billion |
Includes ankylosing spondylitis and Crohn’s disease |
Total biologic sales for the drug's class exceeded USD 22 billion in 2022, with biosimilars capturing around 25% of the market in the same year. Bioequivalent products have increased competition and driven prices downward.
Competition and Biosimilar Dynamics
- Significant biosimilars commercially available.
- Patent expiry for the reference biologic in 2023.
- Entry of generics expected to depress pricing for biosimilars.
- Payers favor biosimilars, leading to increased utilization.
Price Projections and Pricing Trends
Current Pricing Landscape
| Product |
WAC (Wholesale Acquisition Cost) |
Estimated Outpatient Price |
Market Share 2022 |
| Reference biologic |
USD 50,000/year |
USD 40,000–USD 45,000 |
75% |
| Biosimilar (NDC 72733-5901) |
USD 35,000/year |
USD 30,000–USD 33,000 |
25% |
Short-Term Price Trends (2023-2025)
- Biosimilar prices expected to decrease by 10-15% annually.
- Prices could stabilize or slightly decline further as market saturation occurs.
- Price reductions driven by increased biosimilar adoption and payer negotiations.
Long-Term Price Outlook (2026-2030)
- Prices likely to stabilize 10-20% below 2022 levels, factoring in inflation and manufacturing costs.
- Biosimilar market share projected to reach 60-70% by 2030.
- Continued price erosion expected due to competition, fewer patents, and regulatory pressures.
Factors Influencing Future Pricing and Market Penetration
- Patent Litigation Outcomes: Potential delays or accelerations in biosimilar entry.
- Market Access Policies: Payer policies favoring biosimilars can accelerate price declines.
- Innovation and New Indications: Additional approvals could expand total addressable market and impact pricing.
- Manufacturing Costs: Expected to decrease with technological advances, affecting pricing strategies.
Potential Revenue Projections
| Scenario |
2023 |
2025 |
2030 |
| Conservative adoption (15%) market share |
USD 3.5B |
USD 4.2B |
USD 5.0B |
| Aggressive biosimilar adoption (50%) |
USD 11.7B |
USD 14.4B |
USD 18.0B |
These projections assume existing market growth trends, patent status, and biosimilar competition.
Key Takeaways
- The drug faces increasing biosimilar competition with pricing discounts of up to 30% relative to reference biologics.
- Prices are projected to decline 10-15% annually over the next three years.
- Market share growth is likely to favor biosimilars, reducing overall revenue for the originator.
- Regulatory and policy changes could significantly accelerate or slow market penetration and price declines.
- The market presents opportunities for early biosimilar market entry and targeted payer strategies to optimize revenue.
FAQs
1. What factors could disrupt these price projections?
Patent litigation outcomes and regulatory changes can either delay biosimilar entry or accelerate pricing pressures.
2. How does biosimilar uptake affect revenue?
Increased adoption typically leads to volume-driven revenue growth but at significantly lower prices, compressing margins.
3. Which markets are most receptive to biosimilars?
European markets show faster uptake due to supportive policies, while U.S. adoption is driven by payer incentives and formulary management.
4. What is the size of the biosimilar market for this drug class?
It is projected to reach USD 13-16 billion globally by 2025, with a compound annual growth rate of approximately 12%.
5. How should companies strategize for future market share?
Invest in patient and payer education, optimize manufacturing costs, and secure early regulatory approvals to maximize market share.
References
[1] IQVIA. (2022). The Impact of Biosimilars on Pharmaceutical Markets.
[2] FDA. (2023). Biologics Price Competition and Innovation Act.
[3] EvaluatePharma. (2022). Biosimilars Market Outlook.
